As TET2 function is dependent on the metabolites produced by the IDH proteins [21,32], susceptibility to STAT5 and MCL1 inhibitors may be similar in AML cells with IDH mutations, as in TET2 mutated cells. The gene discussed is MCL1; the disease is acute myeloid leukemia.